2025-10-29 08:41:15
Presenters: Maloh J,1 Paldus B,1 Afzal N,1 Sivamani R1
Background: Rosacea is a chronic inflammatory skin condition that is characterized by facial erythema, telangiectasia, and inflammatory lesions. Emerging research suggests that systemic oxidative stress and skin barrier dysfunction may also be associated with this condition.
Objective: To explore the effects of an oral supplement containing antioxidants, and L-histidine, an amino acid found to support the skin barrier, on those with rosacea.
Methods: The study was an open label trial with 20 participants between the ages of 30 to 70 years old with mild to moderate rosacea (erythematotelangiectatic or papulopustular). Inflammatory lesion (IL) counts, the Investigator's Global Assessment (IGA), erythema, and the Rosacea Area and Severity Index (RASI) were measured at baseline, Week 4, and Week 8.
Results: Significant improvements in IGA, erythema, RASI, and IL counts were observed at Week 4 and at Week 8 relative to baseline (Figure 1). This includes a 21% reduction in RASI at Week 4 (p<0.001) and a 46% reduction in RASI at Week 8 (p<0.001).
Conclusion: This study provides preliminary evidence for the use of oral supplementation with antioxidants and L-histidine in the management of rosacea. Further research with larger placebo-controlled trials is needed to confirm these findings and better understand the mechanisms of action of the supplement ingredients in relationship to the pathophysiology of rosacea.
Disclosures: JM serves as a consultant and stockholder for Codex Labs Corp. BP is the founder and CEO of Codex Labs Corp. RKS serves as a scientific advisor and a holder of stock options with Codex Labs, a scientific advisor to Arbonne, and as a consultant to Burt’s Bees, Novozymes, Nutrafol, Abbvie, Leo, Galderma, Pfizer, UCB, Incyte, Sanofi, Novartis, Arcutis, Amgen, Sun and Regeneron Pharmaceuticals
Funding: Codex Labs Corp
©Matrix Medical Communications. View All Articles.